Rybelsus is owned by Novo.
Rybelsus contains Semaglutide.
Rybelsus has a total of 8 drug patents out of which 0 drug patents have expired.
Rybelsus was authorised for market use on 20 September, 2019.
Rybelsus is available in tablet;oral dosage forms.
Rybelsus can be used as method of treating type 2 diabetes mellitus.
The generics of Rybelsus are possible to be released after 02 May, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(2 years from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9278123 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
US11382957 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
US10086047 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(8 years from now) | |
US10960052 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
Dec, 2031
(8 years from now) | |
US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(9 years from now) | |
US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET;ORAL
21
United States
18
European Union
8
Japan
7
Korea, Republic of
7
China
6
Denmark
6
Mexico
6
Hungary
6
Portugal
6
Spain
6
Poland
5
Australia
5
Brazil
4
South Africa
4
Slovenia
4
Russia
4
Croatia
4
RS
4
Canada
3
Israel
3
Lithuania
3
Cyprus
2
Norway
2
Malaysia
2
Taiwan, Province of China
1
Austria
1
Saudi Arabia
1
Germany
1
Netherlands
1
Ukraine
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic